Allena Pharmaceuticals Competitors, Revenue, Alternatives and Pricing
Estimated Revenue & Financials
- Allena Pharmaceuticals's estimated annual revenue is currently $6M per year.
- Allena Pharmaceuticals received $53.0M in venture funding in December 2015.
- Allena Pharmaceuticals's estimated revenue per employee is $116,250
- Allena Pharmaceuticals's total funding is $93M.
- Allena Pharmaceuticals has 52 Employees.
- Allena Pharmaceuticals grew their employee count by 18% last year.
- Allena Pharmaceuticals currently has 5 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Pricing|
|Cell Signaling ...||$89.4M||577||N/A||N/A||N/A|
What Is Allena Pharmaceuticals?
Allena Pharmaceuticals is dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic disorders that affect the kidney. The company is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease. Allena's proprietary technological approach enables the design, formulation and delivery of non-absorbed and stable enzymes orally and in sufficient doses for activity in the GI tract. This approach utilizes the GI tract to degrade metabolites, such as oxalate and urate, reducing plasma and urine levels, and in turn, reducing their disease burden on the kidney over time.keywords:Biotechnology,Cleantech,Healthcare,Mobile,Pharmaceuticals,Wind Power
Number of Employees
Employee Growth %
|Stephen Kraus||Manager, Engineering|
|Hugh Wight||VP Technical Operations|
|Janet Giroux||Manager of Corporate Operations|
|Patrick Norman||Manager Of Contract Manufacturing|
|Jeremy Kerrick||Manager Of Contract Manufacturing||Email Available|
|Kate Hoffman||Director, Clinical & Medical Affairs|
|Todd Banas||Senior Director, Contract Manufacturing|
|Jason Vieira||Qa Manager||Email Available|
|Claire Coleman||Senior Director||Email Available|
|Stephen Yu||Vice President, Quality Assurance|
Allena Pharmaceuticals News
Allena Pharmaceuticals drug, Reloxaliase, is in Phase 3 clinical trials for enteric hyperoxaluria (EH), a leading cause of the most common type ...
Brokerages expect Allena Pharmaceuticals Inc (NASDAQ:ALNA) to report ($0.48) earnings per share (EPS) for the current quarter, according to ...
NEWTON, Mass., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (ALNA), a late-stage, biopharmaceutical company ...
Allena Pharmaceuticals Funding
|2011-11-17||$15.0M||A||Bessemer Venture Partners, Frazier Healthcare||Article|
Allena Pharmaceuticals Executive Hires
|2015-04-17||Louis Brenner||Chief Operating Officer||Article|